Implantable Drug Therapy Articles & Analysis
16 news found
Synchron, an endovascular brain-computer interface (BCI) company, today announced the first human BCI implant in the United States. This procedure represents a significant technological milestone for scalable BCI devices and is the first to occur in the U.S. using an endovascular BCI approach, which does not require invasive open-brain surgery. The procedure was performed at Mount Sinai West in ...
Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. Haggstrom brings an extensive background in medical device commercialization and product launches, with a technical background in R&D engineering, holding over 20 U.S. patents. “I am honored and excited to join the Synchron team and be part of ...
Team Gleason and Synchron, an endovascular brain computer interface company, today announced a partnership agreement to provide patient-focused feedback on their platform to transform daily life for patients with physical and speech disabilities like ALS, muscular dystrophy, and cerebral palsy. The partnership will enable Synchron to collaborate with Team Gleason’s expert committees and an ...
Synchron and Mount Sinai Hospital in New York Advance Industry-First FDA-Approved Clinical Trial for Brain-Computer Interface in U.S. Paralysis is a devastating condition for more than 5 million patients in the United States Synchron, an endovascular brain-computer (BCI) interface company, today announced the enrollment of the first patient in the US clinical trial, COMMAND, for patients ...
Four Patients With ALS Who Received Stentrode™ Implant Gained Ability to Perform Daily Online Tasks No Serious Adverse Events Reported after 12 Months Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of Synchron’s Stentrode™ device, a small mesh-like material inserted ...
It is widely recognized that alternatives to antiepileptic drugs (AEDs) and surgery are a significant unmet medical need, especially for patients with incomplete seizure control who may not be candidates for, or wish to avoid the risks of, surgery and implantable devices. ...
Synchron, a brain computer interface (BCI) company, today announced the expansion of its advisory board comprised of industry pioneers, to provide strategic guidance in support of the Company’s clinical development plans, corporate strategy and growth. The members of the advisory board are visionaries across the technology, neuroscience and medical device industry, which include Edward ...
Melbourne, Australia – February 17, 2022 – PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that the Phase IIa study of its PA5108 Ocular ...
Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, announced today the sale of its in-office MRI system to Kasraeian Urology, a Division of Florida Physician Specialists (“Kasraeian Urology”). FDA cleared for in-office use, the Company’s single-sided MRI system with AI based imaging empowers practices and ...
Synchron, a brain computer interface company, today announced a Twitter takeover by Philip O’Keefe, one of the patients implanted with the Stentrode brain computer interface. Mr. O’Keefe is the first person to successfully message the world on social media directly through thought using an implantable brain computer interface. Mr. O’Keefe, a 62-year-old man with amyotrophic ...
Procedure removes risk of kidney injury or complications in patients with advanced kidney disease or allergy to contrast dye On Sept. 30, CentraCare completed the world’s first contrast-free WATCHMAN implant using 4D holographic therapy guidance, developed by EchoPixel, as the alternative imaging modality. Rather than relying on contrast dye and X-ray based imaging to help guide the ...
GT Medical Technologies, Inc. today announced it is presenting clinical data in two oral presentations on the company's breakthrough GammaTile® Therapy for patients with brain tumors at the 2021 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting. The presenting authors, Dr. David Brachman, co-founder and CTO at GT Medical Technologies and Dr. Mehee Choi, director ...
Patients begin using the device at home soon after implantation and may wirelessly control external devices by thinking about moving their limbs. ...
Alleviant Medical Inc., a privately-held medical device company, today announced that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its transcatheter technology. The technology offers a no-implant interatrial shunt therapy for patients suffering from heart failure with preserved (HFpEF) ...
Justin Beyers will be presenting at CSM 2018 on a poster titled: “Effects of Therapeutic Ultrasound on the Stability of Cemented Simulated Implants. The poster authored by Dr. Peter Bonutti, Justin Beyers, Tonya Bierman, Matt Cremens, and Nicole Tipsword explores the effect of therapeutic ultrasound on cemented implants. The American Physical Therapy Association hosts the annual Combined ...
The jointly developed therapy features a micro-infusion device which tightly controls drug delivery to a region of the brain for patients with medically refractory epilepsy. ...